Bill
HB 3134
Illinois creates a state-run program to import safe, lower-cost Canadian prescription drugs for residents, overseen by IDPH with vendor testing and federal approval.
Status & Key Dates
- Bill number: HB 3134 (introduced 2/18/2025 by Rep. Hoan Huynh).
- Status: Rule 19(a) / Re-referred to Rules Committee. Received from House 5/12/2025 after passage in the House (passed 5/10/2025). Companion: SB 1507.
- Effective date: Immediately upon enactment. Vendor-created import lists due by December 1, 2026 and annually thereafter.
Purpose
- Establish a state-run wholesale prescription drug importation program to allow importation of safe, cost‑saving prescription drugs from Canada for the exclusive benefit of Illinois residents, with an emphasis on maximizing state cost savings while protecting public health and safety.
Major provisions
- Program administration: Creates the Canadian prescription drug importation program within the Illinois Department of Public Health (IDPH). IDPH must adopt implementing rules and, after federal approval (under 21 U.S.C. 384 / HHS authority), contract with one or more private vendors to operate the program.
- Vendor role and procurement: Vendors will (a) develop and annually update a wholesale prescription drug importation list of drugs with the highest potential cost savings (considering shortages, specialty and high‑volume drugs); (b) identify and contract with eligible Canadian suppliers that comply with Canadian federal/provincial laws; (c) assist in distribution and annual reporting. For 3 years after the Act’s effective date, vendor selection is exempt from the Illinois Procurement Code.
- Safety, testing, and supply chain controls: Vendors must verify supplier compliance, and ensure drug safety and quality by statistically sampling and testing shipments (initial shipments fully tested; subsequent shipments sampled) consistent with federal standards. The bill requires supply‑chain documentation, bond requirements for vendors/suppliers, and authority for immediate suspension of specified imported drugs if concerns arise.
- Eligible importers/recipients: Importers may include pharmacists/wholesalers supplying Medicaid pharmacies, the Department of Corrections (for inmates), federally approved commercial plans, and licensed pharmacists or registered wholesalers approved by IDPH. Medicaid pharmacies are explicitly included as recipients.
- Reporting and federal coordination: The vendor and Department must prepare annual reports and notify the state when federal approval is obtained. Federal approval is required before program operation.
Who would be affected
- Direct beneficiaries: Illinois Medicaid recipients, incarcerated individuals, commercial plan enrollees (if included), and other Illinois residents served via participating pharmacies/wholesalers.
- Program participants: IDPH, contracted vendors, licensed pharmacists, wholesalers, and Canadian manufacturers/distributors/pharmacies that meet eligibility.
- Financial/administrative: Potential state cost savings on prescription drug purchases offset by program administrative costs, vendor contracting, testing, and oversight responsibilities.
Potential impacts and considerations
- Potential for reduced drug spending (state and consumer) by importing lower‑cost Canadian drugs.
- Safety controls built in (Canadian regulatory compliance, testing and supply‑chain documentation), but the program depends on robust vendor oversight and final federal approval.
- Short‑term procurement exemption for vendors (3 years) may accelerate vendor selection but raises transparency/accountability considerations.
- Implementation hinges on federal HHS authorization and IDPH rulemaking; actual cost savings and operational feasibility will depend on vendor performance, supplier participation, and the scope of drugs approved for import.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
